Biomedical Engineering Reference
In-Depth Information
164 BIBLIOGRAPHY
[827] Good, A.H., et al.,
Identification of carbohydrate structures that bind human antiporcine antibod-
ies: implications for discordant xenografting in humans.
Transplant Proc, 1992.
24
(2): p. 559-62.
[828] Sandrin, M.S., et al.,
Anti-pig IgM antibodies in human serum react predominantly with
Gal(alpha 1-3)Gal epitopes.
Proc Natl Acad Sci U S A, 1993.
90
(23): p. 11391-5.
[829] Stone, K.R., et al.,
Porcine and bovine cartilage transplants in cynomolgus monkey: I. A model for
chronic xenograft rejection.
Transplantation, 1997.
63
(5): p. 640-5.
[830] Galili, U., et al.,
Porcine and bovine cartilage transplants in cynomolgus monkey: II. Changes in
anti-Gal response during chronic rejection.
Transplantation, 1997.
63
(5): p. 646-51.
[831] Stone, K.R., et al.,
Porcine cartilage transplants in the cynomolgus monkey. III. Transplantation
of alpha-galactosidase-treated porcine cartilage.
Transplantation, 1998.
65
(12): p. 1577-83.
[832] Tearle, R.G., et al.,
The alpha-1,3-galactosyltransferase knockout mouse. Implications for xeno-
transplantation.
Transplantation, 1996.
61
(1): p. 13-9.
[833] Derham, C., et al.,
Tissue
engineering
small-diameter
vascular
grafts:
preparation
of
a
biocompatible
porcine
ureteric
scaffold.
Tissue
Eng
Part
A, 2008.
14
(11): p. 1871-82.
[834]
Compilation of Selected Acts within the Jurisdiction of the Committee on Energy and Commerce:
Food, Drug, and Related Law, as Amended through December 31, 2004
. 109th Congress, 1st
Session, 2005. Washington: U.S. GPO. GPO #: Y4.C73/8:107-D.
[835] Current good manufacturing practice in manufacturing, processing, packing, or holding of
drugs. Title 21 Code of Federal Regulations, Pt. 210. Revised as of April 1, 2009.
[836] Current good manufacturing practice for finished pharmaceuticals. Title 21 Code of Federal
Regulations, Pt. 211. Revised as of April 1, 2009.
[837] Quality system regulation. Title 21 Code of Federal Regulations, Pt. 820. Revised as of April
1, 2009.
[838] Investigational device exemptions. Title 21 Code of Federal Regulations, Pt. 812. Revised as
of April 1, 2009.
[839] Trommelmans, L., J. Selling, and
K. Dierickx,
A
critical
assessment
of
the
directive
on
tissue
engineering
of
the
European
union.
Tissue
Eng,
2007.
13
(4):
p.
667-72.
[840] Brevignon-Dodin,
L.
and
F.
Livesey,
Regulation
of
tissue-engineered
products
in
the
European
Union:
where
are
we
heading?
Regen
Med,
2006.
1
(5):
p.
709-14.
